Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
IPO Year: 2014
Exchange: NASDAQ
Website: pahc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $22.00 | Neutral | JP Morgan |
| 12/7/2023 | $9.00 | Underperform | Exane BNP Paribas |
| 12/21/2022 | $18.00 | Buy | ROTH Capital |
| 7/25/2022 | $22.00 | Equal Weight → Underweight | Barclays |
| 1/10/2022 | $23.00 | Underweight → Equal-Weight | Barclays |
| 11/18/2021 | $23.00 | Equal-Weight | Morgan Stanley |
| 8/5/2021 | $25.00 | Neutral | Credit Suisse |
| 7/7/2021 | $23.00 | Equal-Weight → Underweight | Barclays |
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1 million, or 13% Net income of $7.0 million, an increase of $15.0 million Diluted income per share of $0.17, an increase of $0.37 Adjusted EBITDA of $30.7 million, an increase of $12.0 million, or 64% Adjusted net income of $14.1 million, an increase of $8.6 million Adjusted diluted EPS of $0.35,
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vi
Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition for better lives and a more sustainable world. "Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro's species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world," said Jack C
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To acc
Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on Thursday, September 5, 2024, at 1:05 PM ET at the New York Marriott Marquis. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal h
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2024 and provided its financial guidance for the year ending June 30, 2025. Highlights for the three months ended June 30, 2024 (compared to the three months ended June 30, 2023) Net sales of $273.2 million, an increase of $18.1 million, or 7% Net income of $0.8 million, a decrease of $10.7 million Diluted earnings per share of $0.02, a decrease of $0.26 Adjusted EBITDA of $33.4 million, an increase of $1.1 million, or 3% Adjusted net income of $16.7 million, an increase of $1.5 million, or 10% Adjusted diluted
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 25, 2024, to stockholders of record at the close of business on September 4, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please
Phibro Animal Health Corporation (NASDAQ:PAHC) proudly announces its third annual Environmental, Social and Governance (ESG) Report, highlighting 2023 achievements. At Phibro, the connections between people, animals and the planet drive us to optimize animal health and nutrition for better lives and a sustainable world. "Phibro's business segments naturally align with today's ESG and corporate responsibility mindset," said Jack Bendheim, President, CEO and Chairman of the Board. "We help farmers become more efficient and sustainable by preventing animal disease, reducing waste and conserving resources. This results in a safer, more affordable food supply for society." Recent research co
Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference. Chief Financial Officer, Glenn David along with Larry Miller, Chief Operating Officer and EVP Corporate Strategy, Daniel Bendheim will address financial analysts and investors on Wednesday, May 29, 2024, at 10:20 AM ET at the St. Regis New York. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corpo
Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ -- TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
10-Q - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
SCHEDULE 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
DEFA14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
DEF 14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
10-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1 million, or 13% Net income of $7.0 million, an increase of $15.0 million Diluted income per share of $0.17, an increase of $0.37 Adjusted EBITDA of $30.7 million, an increase of $12.0 million, or 64% Adjusted net income of $14.1 million, an increase of $8.6 million Adjusted diluted EPS of $0.35,
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vi
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To acc
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2024 and provided its financial guidance for the year ending June 30, 2025. Highlights for the three months ended June 30, 2024 (compared to the three months ended June 30, 2023) Net sales of $273.2 million, an increase of $18.1 million, or 7% Net income of $0.8 million, a decrease of $10.7 million Diluted earnings per share of $0.02, a decrease of $0.26 Adjusted EBITDA of $33.4 million, an increase of $1.1 million, or 3% Adjusted net income of $16.7 million, an increase of $1.5 million, or 10% Adjusted diluted
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 25, 2024, to stockholders of record at the close of business on September 4, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its third quarter ended March 31, 2024, and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023) Net sales of $263.2 million, an increase of $17.6 million, or 7% Net income of $8.4 million, a decrease of $1.6 million Diluted earnings per share of $0.21, a decrease of $0.04 Adjusted EBITDA of $29.7 million, an increase of $2.3 million, or 9% Adjusted net income of $12.7 million, an increase of $1.1 million, or 9% Adjusted diluted EPS of $0.31, a
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 26, 2024, to stockholders of record at the close of business on June 5, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.p
Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (NASDAQ:PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428775498/en/ Both Zoetis and Phibro Animal Health have a longstanding commitment to the production animal health sector. The acquired product portfolio
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its third quarter financial results on Wednesday, May 8, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 9, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the
JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00
Exane BNP Paribas initiated coverage of Phibro Animal Health with a rating of Underperform and set a new price target of $9.00
ROTH Capital initiated coverage of Phibro Animal Health with a rating of Buy and set a new price target of $18.00
Barclays downgraded Phibro Animal Health from Equal Weight to Underweight and set a new price target of $22.00
Barclays upgraded Phibro Animal Health from Underweight to Equal-Weight and set a new price target of $23.00
Morgan Stanley initiated coverage of Phibro Animal Health with a rating of Equal-Weight and set a new price target of $23.00
Credit Suisse resumed coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $25.00
Barclays downgraded Phibro Animal Health from Equal-Weight to Underweight and set a new price target of $23.00
Morgan Stanley reiterated coverage of Phibro Animal Health with a rating of Underweight and set a new price target of $22.00 from $19.00 previously
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:PAHC) with a Underweight and raises the price target from $10 to $13.
Phibro Animal Health (NASDAQ:PAHC) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.29 by 6.9 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $263.200 million which beat the analyst consensus estimate of $254.825 million by 3.29 percent. This is a 7.12 percent increase over sales of $245.700 million the same period last year.
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister its Securities to terminate and suspend its reporting obligations. Clever Leaves Holdings shares dipped 60% to $1.6498 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares climbed 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash. Collective Audience, Inc. (NASDAQ:CAUD) gained 50.4% to $0.6002 after the company announced a strategic partne
Gainers Deciphera Pharmaceuticals (NASDAQ:DCPH) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Calidi Biotherapeutics (AMEX:CLDI) shares rose 51.46% to $0.24. The market value of their outstanding shares is at $11.9 million. SINTX Techs (NASDAQ:SINT) stock moved upwards by 32.17% to $0.05. The market value of their outstanding shares is at $6.5 million. Koninklijke Philips (NYSE:PHG) stock moved upwards by 28.02% to $26.98. The company's market cap stands at $24.4 billion. As per the news, the Q1 earnings report came out today. Phibro Animal Health (NASDAQ:PAHC) shares rose 26.94% to $16.16. The ma
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China. Tesla shares jumped 10.5% to $185.94 on Monday. Here are some other big stocks recording gains in today's session. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares surged 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash. ImmunityBio, Inc. (NASDAQ:IBRX) shares rose 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company annou
Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (NASDAQ:PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. This press release features multimedia. View the full release here:
We affirm our previously issued fiscal year 2024 guidance for the following measures:Net sales of $980 million to $1.020 billionAdjusted EBITDA of $106 million to $112 millionAdjusted net income of $42 million to $47 million, andAdjusted diluted EPS of $1.04 to $1.16
Phibro Animal Health (NASDAQ:PAHC) reported its Q2 earnings results on Wednesday, February 7, 2024 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Phibro Animal Health beat estimated earnings by 17.86%, reporting an EPS of $0.33 versus an estimate of $0.28. Revenue was up $5.30 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.09 which was followed by a 18.52% drop in the share price the next day. Here's a look at Phibro Animal Health's past performance: Quarter Q1 2024 Q4 2023 Q3 2023 Q2 2023 EPS Estimate 0.23 0.40 0.33 0.30 EPS Actual 0.14 0.38 0.29 0.34 Revenue Estimate 242.04M 258.55M